Authors discuss nephrotoxicity of aminoglycosides in patients with hepatic and biliary disorders. It may be concluded that hepatic and biliary diseases should be considered as an additional gentamycin nephrotoxicity risk factor. Administration of gentamycin to such patients require dose adjustments to renal function and--if possible--to gentamycin serum level.